Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CAB-ROR2-ADC (Primary)
  • Indications Advanced breast cancer; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BioAtla

    • Most Recent Events

    • 28 Jun 2018 According to a Bioatla media release, first patient clinical study was enrolled and dosed at Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN under the direction of the principal investigator, Howard A.
    • 12 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 19 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top